Traduction de «Contribution method » (Anglais → Français) :

contribution method of allocating profits

level cost methods [ level contribution methods ]

level cost methods | level contribution methods

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

contribution offset integration method | contribution offset integration

contribution formula method | contribution formula

contribution formula integration method [ contribution formula integration ]

contribution | insurance contribution | national insurance contribution | social contribution | social security contribution

method of collection by means of contribution

I would put in a request, if your department would like, to table into this committee the objectives, method of selection, and measurement used in those grants and contributions; the overarching philosophy CIDA is using; the objectives for those grants and contributions; the method of selection as to who gets them; and how we measure the outcomes of those activities.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Can ...[+++]adian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

7. Believes that both the first and second pillar should contribute to achieving greener modes of production as they are of different scope and objective; therefore, under the second pillar, there is a need to create mechanisms stimulating the growth of energy efficiency (p.ex. thermal modernisation of buildings, replacement of the equipment for less energy intensive, heat recuperation or use of the solar energy) as well as the efforts which cannot be undertaken by the individual farmer and that would enable farmers to engage in a more effective and greener energy production and more sustainable production ...[+++]methods and to meet tomorrow's challenges: competitiveness, adaptation to markets, value creation, preservation of natural resources, adaptation to climate change etc.; calls for the Commission to prepare an industrial research platform within FP8 and enable increased participation by the agricultural industry in the research framework programmes that would include research and innovation of new techniques and methods, such as development of intelligent and highly productive crops, sustainable weeding methods and efficient separation of manure;

the current reorganisation of the JRC Institute for Health and Consumer Protection (IHCP) will make an important contribution to accelerating the on-going efforts to advance alternative methods, including their validation, via ECVAM. This will involve reinforcement of ECVAM's work through support by other IHCP teams. The IHCP is also developing an integrated testing strategy which will leverage the synergies of many complementary activities within the IHCP and allow a more holistic and effective approach to the question of risk assess ...[+++]ment, which is central to the regulatory process, thus avoiding unnecessary internal transmission delays. The integrated testing team will, in 2009, consist of about 85 staff members (including the present 62 ECVAM staff members). As part of its contribution to streamlining the process from scientific validation to regulatory acceptance, IHCP will ensure close and consistent follow-up of the regulatory acceptance process both within the Commission and at the level of the OECD;